Ellen Feigal

Directeur/Bestuurslid bij XENCOR, INC.

Vermogen: 65 304 $ op 31-05-2026

71 jaar

Connecties 63

Consumer Services

Health Technology

Commercial Services

Profiel

Ellen G.
Feigal currently works at Foundation For Cell & Gene Medicine, as Director, Prescient Therapeutics Ltd., as Non-Executive Director from 2023, NextCure, Inc., as Independent Director from 2021, Xencor, Inc., as Independent Director from 2018, and NDA Partners LLC, as Partner & Head-Biologics Practice from 2014.
Dr. Feigal also formerly worked at Amgen, Inc., as Executive Medical Director-Global Development from 2008 to 2011, The University of California, San Francisco, as Director, National Cancer Institute, as Deputy Director-Cancer Treatment Division, Critical Path Institute, as Director-Medical Devices & Imaging from 2006 to 2007, the University of California, as Director-American Course on Drug Development from 2006 to 2011, Translational Genomics Research Institute, as Vice President-Clinical Sciences from 2004 to 2007, INSYS Therapeutics, Inc., as Chief Medical Officer from 2007 to 2008, and California Institute for Regenerative Medicine, as Vice President-Research & Development from 2011 to 2014.
Dr. Feigal received her graduate degree from the University of California, Berkeley, doctorate degree from the University of California, Davis, undergraduate degree from the University of Minnesota, and doctorate degree from Stanford University School of Medicine.

Bekende belangen in openbare bedrijven

Onderneming	Datum	Aantal aandelen	Totale waarde	Waarderingsdatum
XENCOR, INC. 0,01%	28-02-2026	5.497 ( 0,01% )	65 304 $	31-05-2026
NEXTCURE, INC. -.--%	22-04-2026	0 ( -.--% )	- $	31-05-2026
PRESCIENT THERAPEUTICS LIMITED -.--%	30-06-2025	0 ( -.--% )	- $	31-05-2026

Actieve functies van Ellen Feigal

Bedrijven	Functie	Begin
NEXTCURE, INC.	Directeur/Bestuurslid	01-10-2021
PRESCIENT THERAPEUTICS LIMITED	Directeur/Bestuurslid	15-05-2023
XENCOR, INC.	Directeur/Bestuurslid	01-11-2018
NDA Partners LLC NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services	Corporate Officer/Principal	01-12-2014
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine.	Directeur/Bestuurslid	-

Alle actieve functies van Ellen Feigal

Eerdere bekende functies van Ellen Feigal

Bedrijven	Functie	Einde
California Institute for Regenerative Medicine California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services	Hoofd Techniek/Wetenschap/O&O	01-12-2014
University of California University of California Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	01-01-2011
AMGEN INC.	Corporate Officer/Principal	01-01-2011
INSYS THERAPEUTICS, INC.	Hoofd Techniek/Wetenschap/O&O	01-01-2008
░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░

Ervaring van Ellen Feigal in detail bekijken

Opleiding van Ellen Feigal

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Ellen Feigal in detail bekijken

Connecties

Eerstegraads connecties

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit	17
Amgen, Inc. Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics	Health Technology
Xencor, Inc. Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions	Health Technology
Prescient Therapeutics Ltd. Prescient Therapeutics Ltd. BiotechnologyHealth Technology Operates as a a clinical stage oncology company	Health Technology
University of California, Berkeley University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of California, Davis University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Minnesota University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The University of California, San Francisco The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
National Cancer Institute National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research	Miscellaneous
California Institute for Regenerative Medicine California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services	Government
NDA Partners LLC NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services	Commercial Services
Translational Genomics Research Institute Translational Genomics Research Institute Miscellaneous Commercial ServicesCommercial Services Operates as a cancer, neurological disorders and infectious disease medical research institute	Commercial Services
Critical Path Institute Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Provides medical drug and product development review process	Commercial Services
INSYS Therapeutics, Inc. INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty pharmaceutical company	Health Technology
University of California University of California Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Stanford University School of Medicine Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
NextCure, Inc. NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases	Health Technology
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine.